RSLV 132

Drug Profile

RSLV 132

Alternative Names: RSLV-132

Latest Information Update: 31 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Washington University
  • Developer Resolve Therapeutics
  • Class Anti-inflammatories; Biological proteins; Recombinant fusion proteins
  • Mechanism of Action B cell inhibitors; Interferon alpha inhibitors; Ribonuclease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 01 Aug 2018 Resolve Therapeutics completes a phase II trial in Sjogren's syndrome (Treatment-experienced) in United Kingdom (IV) (NCT03247686)
  • 10 Feb 2016 Efficacy, adverse events and pharmacokinetics data from a phasee I trial in Systemic lupus erythematosus released by Resolve Therapeutics
  • 01 Jan 2016 Phase-II clinical trials in Systemic lupus erythematosus in USA (IV) (NCT02660944)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top